Shopping Cart
- Remove All
Your shopping cart is currently empty
Tipelukast
😃Good
Catalog No. T15647Cas No. 125961-82-2
Alias MN 001, KCA 757
Tipelukast (KCA 757) is a novel, orally available leukotriene receptor antagonist with anti-inflammatory properties, capable of reducing fibrosis and down-regulating TIMP-1 and type 1 collagen. Tipelukast is utilized in asthma research.
Tipelukast
😃Good
Purity: 100%
Catalog No. T15647Alias MN 001, KCA 757Cas No. 125961-82-2
Tipelukast (KCA 757) is a novel, orally available leukotriene receptor antagonist with anti-inflammatory properties, capable of reducing fibrosis and down-regulating TIMP-1 and type 1 collagen. Tipelukast is utilized in asthma research.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $323 | Backorder | |
| 5 mg | $788 | Backorder | |
| 10 mg | $1,080 | Backorder | |
| 25 mg | $1,630 | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Tipelukast"
Montelukast sodium
MK0476
T1677L151767-02-1
Montelukast sodium (MK0476) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.
- $41
Size
QTY
L 674573
L-674573, L674573, L-674,573, L674,573, L 674,573
T24327127481-29-2
L 674573 is an inhibitor of leukotriene biosynthesis.
- $50
Size
QTY
ABT-080
VML-530, VML530, VML 530, ABT080
T26524189498-57-5
ABT-080 (VML 530), a leukotriene synthesis inhibitor, is used potentially for treatment of asthma.
- $50
Size
QTY
CGP 35949
CGP-35949, Cgp-35949, Cgp35949, CGP35949
T30828111130-13-3In house
CGP 35949 is an LTD4 antagonist with phospholipase inhibitory activity.
- $70
Size
QTY
Montelukast
Cited
Singular
T1677158966-92-8
Montelukast (Singular) is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.
- $29
Size
QTY
CitedREV 5901A
REV 5901A（101910-24-1 Free base）, REV 5901 HCl
T21821L92532-23-5In house
REV 5901A (REV 5901 HCl) is an orally active leukotriene receptor antagonist and 5-lipoxygenase inhibitor with antimicrobial activity that attenuates colon cancer growth in mice.REV 5901A has been used in studies of asthma and myocardial infarction. REV 5901A is used to study asthma and myocardial infarction.
- $195
Size
QTY
Masilukast
ZD-3523, SA-09012, MCC-847, ICI-D-3523, ICI D-3523, D-3523
T27979136564-68-6In house
Masilukast(MCC-847) is an oral leukotriene D4 (LTD4) receptor antagonist for the study of diseases associated with inflammation.
- $526
Size
QTY
MK-571 sodium Cited
Verlukast sodium, MK-571 sodium salt, MK571 sodium, L-660711 sodium salt, L-660711 (sodium salt)
T3148115103-85-0
MK-571 sodium (L-660711 sodium salt) is a selective, orally active antagonist of the CysLT1 receptor. MK-571 sodium is a multidrug resistance protein-2 (ABCC2, Mrp2) inhibitor used to demonstrate the role of Mrp2 in the cellular efflux of drugs, xenobiotics, and their conjugates. MK-571 sodium can inhibit the synthesis of K-4′-O-GlcA (19.7 μM). MK571 dose-dependently inhibits the intracellular biosynthesis of all flavonol sulphates and glucuronides by Caco-2 cells. MK-571 sodium significantly inhibits phase-2 conjugation of kaempferol by cell-free extracts of Caco-2, and production of kaempferol-4′-O-glucuronide was competitively inhibited. In addition to inhibiting MRP2, MK571 is a potent inhibitor of enterocyte phase-2 conjugation.
- $47
Size
QTY
CitedPranlukast Cited
ONO-1078
T0694103177-37-3
Pranlukast (ONO-1078) is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
- $50
Size
QTY
CitedL 651896
L-651896, L651896
T2430699134-29-9In house
L 651896 is a novel leukotriene biosynthesis and 5-lipoxygenase inhibitor for the study of respiratory and cardiovascular diseases.
- $333
Size
QTY
LY255283
LY 255283
T22946117690-79-6
LY255283 is a specific antagonit of leukotriene B4 (LTB4) receptor. It inhibits the production of LTB(4) in human peripheral blood polymorphonuclear leukocytes (PMNL) and in monocytes activated by calcium ionophore A23187.
- $39
Size
QTY
RG 7152
RG-7152, RG7152
T28529107813-63-8In house
RG 7152 is a leukotriene D4 antagonist with anti-asthmatic properties and can be used in the study of asthma.
- $293
Size
QTY
Select Batch
Purity:100%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Tipelukast (KCA 757) is a novel, orally available leukotriene receptor antagonist with anti-inflammatory properties, capable of reducing fibrosis and down-regulating TIMP-1 and type 1 collagen. Tipelukast is utilized in asthma research. |
| Targets&IC50 | LTD4:6.41 (pA2,guinea-pigs), LTD4 receptor:2.3 μmol (pulmonary cell membrane), LTE4:6.45 (pA2,guinea-pigs) |
| In vitro | Tipelukast inhibits the binding of [3H] LTD4 to the LTD4 receptors on the pulmonary cell membrane of guinea-pigs (IC50 = 2.3 μmol)[1]. |
| In vivo | Fifteen minutes after an aerosolized antigen challenge, and inhaled 5 minutes later into the guinea pigs, Tipelukast significantly modifies the bronchoconstriction induced by UNDW[1]. Intravenous administration of Tipelukast (1 and 5 mg/kg) 15 minutes after antigen challenge dose-dependently reduces propranolol-induced bronchoconstriction (PIB) in guinea-pigs[1]. |
| Alias | MN 001, KCA 757 |
| Molecular Weight | 530.67 |
| Formula | C29H38O7S |
| Cas No. | 125961-82-2 |
| Smiles | CCCc1c(O)c(ccc1SCCCOc1ccc(C(C)=O)c(OCCCC(O)=O)c1CCC)C(C)=O |
| Relative Density. | 1.22 |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol: < 1 mg/mL |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Tipelukast | purchase Tipelukast | Tipelukast cost | order Tipelukast | Tipelukast chemical structure | Tipelukast in vivo | Tipelukast in vitro | Tipelukast formula | Tipelukast molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.